CoChat
Sign Up
Cited by 100RNA Interference and Gene DeliveryRNA and protein synthesis mechanismsRNA Research and Splicing

Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics

Open access
Kang, Diana D., Li, Haoyuan, Dong, Yizhou·2023·Advanced Drug Delivery Reviews
DOI 10.1016/j.addr.2023.114961PMC PMC10264168
Open this paper in CoChat — free account

Abstract

The accelerated progress and approval of two mRNA-based vaccines to address the SARS-CoV-2 virus were unprecedented. This record-setting feat was made possible through the solid foundation of research on in vitro transcribed mRNA (IVT mRNA) which could be utilized as a therapeutic modality. Through decades of thorough research to overcome barriers to implementation, mRNA-based vaccines or therapeutics offer many advantages to rapidly address a broad range of applications including infectious diseases, cancers, and gene editing. Here, we describe the advances that have supported the adoption of IVT mRNA in the clinics, including optimization of the IVT mRNA structural components, synthesis, and lastly concluding with different classes of IVT RNA. Continuing interest in driving IVT mRNA technology will enable a safer and more efficacious therapeutic modality to address emerging and existing diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.addr.2023.114961

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 112

  1. [1]Brenner S. Jacob F. Meselson M. An unstable intermediate carrying information from genes to ribosomes for protein synthesis Nature 190 1961 576 581 10.1038/190576a0 20446365 · DOI
  2. [2]Yan J. Kang D.D. Dong Y. Harnessing lipid nanoparticles for efficient CRISPR delivery Biomater. Sci. 9 18 2021 6001 6011 34115079 PMC8440433
  3. [3]Barbier A.J. Jiang A.Y. Zhang P. Wooster R. Anderson D.G. The clinical progress of mRNA vaccines and immunotherapies Nat. Biotechnol. 40 2022 840 854 10.1038/s41587-022-01294-2 35534554 · DOI · Paper page
  4. [7]Nallagatla S.R. Bevilacqua P.C. Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner RNA 14 2008 1201 1213 10.1261/rna.1007408 18426922 PMC2390794 · DOI
  5. [9]Bornewasser L. Domnick C. Kath-Schorr S. Stronger together for in-cell translation: natural and unnatural base modified mRNA Chem. Sci. 13 2022 4753 4761 10.1039/d2sc00670g 35655897 PMC9067582 · DOI
  6. [10]Andries O. Mc Cafferty S. De Smedt S.C. Weiss R. Sanders N.N. Kitada T. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice J. Control. Release 217 2015 337 344 26342664
  7. [12]Wayment-Steele H.K. Kim D.S. Choe C.A. Nicol J.J. Wellington-Oguri R. Watkins A.M. Parra Sperberg R.A. Huang P.S. Participants E. Das R. Theoretical basis for stabilizing messenger RNA through secondary structure design Nucl. Acids Res. 49 18 2021 10604 10617 34520542 PMC8499941
  8. [16]Li B. Luo X. Dong Y. Effects of Chemically Modified Messenger RNA on Protein Expression Bioconjug Chem 27 2016 849 853 10.1021/acs.bioconjchem.6b00090 26906521 · DOI
  9. [20]Verbeke R. Hogan M.J. Lore K. Pardi N. Innate immune mechanisms of mRNA vaccines Immunity 55 2022 1993 2005 10.1016/j.immuni.2022.10.014 36351374 PMC9641982 · DOI
  10. [22]von Roretz C. Di Marco S. Mazroui R. Gallouzi I.E. Turnover of AU-rich-containing mRNAs during stress: a matter of survival Wires Rna 2 2011 336 347 10.1002/wrna.55 21957021 · DOI
  11. [24]Kudla G. Lipinski L. Caffin F. Helwak A. Zylicz M. Hurst L.D. High guanine and cytosine content increases mRNA levels in mammalian cells PLoS Biol 4 6 2006 e180 16700628 PMC1463026
  12. [26]Ramanathan A. Robb G.B. Chan S.H. mRNA capping: biological functions and applications Nucleic Acids Res 44 2016 7511 7526 10.1093/nar/gkw551 27317694 PMC5027499 · DOI
  13. [27]Schwer B. Mao X. Shuman S. Accelerated mRNA decay in conditional mutants of yeast mRNA capping enzyme Nucleic Acids Res 26 1998 2050 2057 10.1093/nar/26.9.2050 9547258 PMC147543 · DOI
  14. [28]Li Y. Kiledjian M. Regulation of mRNA decapping Wiley Interdiscip Rev RNA 1 2010 253 265 10.1002/wrna.15 21935889 PMC13110874 · DOI
  15. [29]Galloway A. Cowling V.H. mRNA cap regulation in mammalian cell function and fate Biochim Biophys Acta Gene Regul Mech 1862 3 2019 270 279 30312682 PMC6414751
  16. [30]Wang S.P. Deng L. Ho C.K. Shuman S. Phylogeny of mRNA capping enzymes Proc Natl Acad Sci U S A 94 1997 9573 9578 10.1073/pnas.94.18.9573 9275164 PMC23221 · DOI
  17. [31]Shuman S. The mRNA capping apparatus as drug target and guide to eukaryotic phylogeny Cold Spring Harb Symp Quant Biol 66 2001 301 312 10.1101/sqb.2001.66.301 12762032 · DOI
  18. [32]McCracken S. 5'-Capping enzymes are targeted to pre-mRNA by binding to the phosphorylated carboxy-terminal domain of RNA polymerase II Genes Dev 11 1997 3306 3318 10.1101/gad.11.24.3306 9407024 PMC316822 · DOI
  19. [33]Furuichi Y. Shatkin A.J. Viral and cellular mRNA capping: past and prospects Adv Virus Res 55 2000 135 184 10.1016/s0065-3527(00)55003-9 11050942 PMC7131690 · DOI
  20. [34]Daffis S. Szretter K.J. Schriewer J. Li J. Youn S. Errett J. Lin T.-Y. Schneller S. Zust R. Dong H. Thiel V. Sen G.C. Fensterl V. Klimstra W.B. Pierson T.C. Buller R.M. Gale Jr M. Shi P.-Y. Diamond M.S. 2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members Nature 468 7322 2010 452 456 21085181 PMC3058805
  21. [35]Leppek K. Das R. Barna M. Functional 5' UTR mRNA structures in eukaryotic translation regulation and how to find them Nat Rev Mol Cell Biol 19 2018 158 174 10.1038/nrm.2017.103 29165424 PMC5820134 · DOI · Paper page
  22. [36]Araujo P.R. Yoon K. Ko D. Smith A.D. Qiao M. Suresh U. Burns S.C. Penalva L.O.F. Before It Gets Started: Regulating Translation at the 5' UTR Comp Funct Genomics 2012 2012 475731 PMC3368165 22693426
  23. [39]Zeng C. Hou X. Yan J. Zhang C. Li W. Zhao W. Du S. Dong Y. Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2 Antigens In Vivo Adv Mater 32 40 2020 e2004452 32875709 PMC8191860
  24. [41]Wang Z. Day N. Trifillis P. Kiledjian M. An mRNA stability complex functions with poly(A)-binding protein to stabilize mRNA in vitro Mol Cell Biol 19 1999 4552 4560 10.1128/MCB.19.7.4552 10373504 PMC84253 · DOI · Paper page
  25. [42]Ferizi M. Aneja M.K. Balmayor E.R. Badieyan Z.S. Mykhaylyk O. Rudolph C. Plank C. Human cellular CYBA UTR sequences increase mRNA translation without affecting the half-life of recombinant RNA transcripts Sci Rep 6 1 2016 10.1038/srep39149 PMC5156912 27974853 · DOI
  26. [43]Jia L. Mao Y. Ji Q. Dersh D. Yewdell J.W. Qian S.-B. Decoding mRNA translatability and stability from the 5' UTR Nat Struct Mol Biol 27 9 2020 814 821 32719458
  27. [44]Cannarozzi G. Schraudolph N.N. Faty M. von Rohr P. Friberg M.T. Roth A.C. Gonnet P. Gonnet G. Barral Y. A role for codon order in translation dynamics Cell 141 2 2010 355 367 20403329
  28. [47]Narula A. Ellis J. Taliaferro J.M. Rissland O.S. Coding regions affect mRNA stability in human cells RNA 25 2019 1751 1764 10.1261/rna.073239.119 31527111 PMC6859850 · DOI
  29. [48]Choi J. Ieong K.-W. Demirci H. Chen J. Petrov A. Prabhakar A. O'Leary S.E. Dominissini D. Rechavi G. Soltis S.M. Ehrenberg M. Puglisi J.D. N(6)-methyladenosine in mRNA disrupts tRNA selection and translation-elongation dynamics Nat Struct Mol Biol 23 2 2016 110 115 26751643 PMC4826618
  30. [49]Eyler D.E. Franco M.K. Batool Z. Wu M.Z. Dubuke M.L. Dobosz-Bartoszek M. Jones J.D. Polikanov Y.S. Roy B. Koutmou K.S. Pseudouridinylation of mRNA coding sequences alters translation Proc Natl Acad Sci U S A 116 46 2019 23068 23074 31672910 PMC6859337
  31. [50]Mao Y. Dong L. Liu X.-M. Guo J. Ma H. Shen B. Qian S.-B. m(6)A in mRNA coding regions promotes translation via the RNA helicase-containing YTHDC2 Nat Commun 10 1 2019 10.1038/s41467-019-13317-9 PMC6877647 31767846 · DOI
  32. [52]Kislauskis E.H. Singer R.H. Determinants of mRNA localization Curr Opin Cell Biol 4 1992 975 978 10.1016/0955-0674(92)90128-y 1485968 · DOI
  33. [53]Mayr C. What Are 3' UTRs Doing? Cold Spring Harb Perspect Biol 11 10 2019 a034728 30181377 PMC6771366
  34. [54]Andreassi C. Riccio A. To localize or not to localize: mRNA fate is in 3'UTR ends Trends Cell Biol 19 2009 465 474 10.1016/j.tcb.2009.06.001 19716303 · DOI
  35. [55]Lytle J.R. Yario T.A. Steitz J.A. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR Proc Natl Acad Sci U S A 104 2007 9667 9672 10.1073/pnas.0703820104 17535905 PMC1887587 · DOI
  36. [56]Brown B.D. Gentner B. Cantore A. Colleoni S. Amendola M. Zingale A. Baccarini A. Lazzari G. Galli C. Naldini L. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state Nat Biotechnol 25 12 2007 1457 1467 18026085
  37. [57]Sandberg R. Neilson J.R. Sarma A. Sharp P.A. Burge C.B. Proliferating cells express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites Science 320 2008 1643 1647 10.1126/science.1155390 18566288 PMC2587246 · DOI · Paper page
  38. [58]Gillies J.K. Lorimer I.A. Regulation of p27Kip1 by miRNA 221/222 in glioblastoma Cell Cycle 6 2007 2005 2009 10.4161/cc.6.16.4526 17721077 · DOI
  39. [60]Lai W.C. Intrinsically Unstructured Sequences in the mRNA 3' UTR Reduce the Ability of Poly(A) Tail to Enhance Translation J Mol Biol 434 2022 167877 10.1016/j.jmb.2022.167877 PMC9750134 36368412 · DOI
  40. [61]Mockey M. Gonçalves C. Dupuy F.P. Lemoine F.M. Pichon C. Midoux P. mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level Biochem Biophys Res Commun 340 4 2006 1062 1068 16403444
  41. [62]Meijer H.A. Bushell M. Hill K. Gant T.W. Willis A.E. Jones P. de Moor C.H. A novel method for poly(A) fractionation reveals a large population of mRNAs with a short poly(A) tail in mammalian cells Nucleic Acids Res 35 19 2007 e132 17933768 PMC2095794
  42. [63]Park J. Kim M. Yi H. Baeg K. Choi Y. Lee Y.-S. Lim J. Kim V.N. Short poly(A) tails are protected from deadenylation by the LARP1-PABP complex Nat Struct Mol Biol 30 3 2023 330 338 36849640
  43. [64]Passmore L.A. Coller J. Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression Nat Rev Mol Cell Biol 23 2022 93 106 10.1038/s41580-021-00417-y 34594027 PMC7614307 · DOI
  44. [65]Legnini I. Alles J. Karaiskos N. Ayoub S. Rajewsky N. FLAM-seq: full-length mRNA sequencing reveals principles of poly(A) tail length control Nat Methods 16 2019 879 886 10.1038/s41592-019-0503-y 31384046 · DOI
  45. [66]Li C.Y. Cytidine-containing tails robustly enhance and prolong protein production of synthetic mRNA in cell and in vivo Mol Ther Nucleic Acids 30 2022 300 310 10.1016/j.omtn.2022.10.003 36320322 PMC9614650 · DOI
  46. [67]Zhao J. Hyman L. Moore C. Formation of mRNA 3' ends in eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA synthesis Microbiol Mol Biol Rev 63 1999 405 445 10.1128/MMBR.63.2.405-445.1999 10357856 PMC98971 · DOI
  47. [68]Chaudhary N. Weissman D. Whitehead K.A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation Nat Rev Drug Discov 20 2021 817 838 10.1038/s41573-021-00283-5 34433919 PMC8386155 · DOI · Paper page
  48. [69]Caruthers M.H. A brief review of DNA and RNA chemical synthesis Biochem Soc Trans 39 2011 575 580 10.1042/BST0390575 21428942 · DOI
  49. [70]Tabor S. Richardson C.C. A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes Proc Natl Acad Sci U S A 82 1985 1074 1078 10.1073/pnas.82.4.1074 3156376 PMC397196 · DOI
  50. [71]Beckert B. Masquida B. Synthesis of RNA by in vitro transcription Methods Mol Biol 703 2011 29 41 10.1007/978-1-59745-248-9_3 21125481 · DOI
  51. [72]Thiel V. Herold J. Schelle B. Siddell S.G. Infectious RNA transcribed in vitro from a cDNA copy of the human coronavirus genome cloned in vaccinia virus J Gen Virol 82 2001 1273 1281 10.1099/0022-1317-82-6-1273 11369870 · DOI
  52. [73]Milligan J.F. Groebe D.R. Witherell G.W. Uhlenbeck O.C. Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates Nucleic Acids Res 15 1987 8783 8798 10.1093/nar/15.21.8783 3684574 PMC306405 · DOI
  53. [74]Rong M. He B. McAllister W.T. Durbin R.K. Promoter specificity determinants of T7 RNA polymerase Proc Natl Acad Sci U S A 95 1998 515 519 10.1073/pnas.95.2.515 9435223 PMC18451 · DOI
  54. [75]Conrad T. Plumbom I. Alcobendas M. Vidal R. Sauer S. Maximizing transcription of nucleic acids with efficient T7 promoters Commun Biol 3 2020 439 10.1038/s42003-020-01167-x 32796901 PMC7429497 · DOI
  55. [76]Dunn J.J. Studier F.W. Gottesman M. Complete nucleotide sequence of bacteriophage T7 DNA and the locations of T7 genetic elements J Mol Biol 166 4 1983 477 535 6864790
  56. [77]Kholod N. Vassilenko K. Shlyapnikov M. Ksenzenko V. Kisselev L. Preparation of active tRNA gene transcripts devoid of 3'-extended products and dimers Nucleic Acids Res 26 1998 2500 2501 10.1093/nar/26.10.2500 9580706 PMC147566 · DOI
  57. [78]Helm M. Brule H. Giege R. Florentz C. More mistakes by T7 RNA polymerase at the 5' ends of in vitro-transcribed RNAs RNA 5 1999 618 621 10.1017/s1355838299982328 10334331 PMC1369788 · DOI
  58. [79]Gholamalipour Y. Karunanayake Mudiyanselage A. Martin C.T. 3' end additions by T7 RNA polymerase are RNA self-templated, distributive and diverse in character-RNA-Seq analyses Nucleic Acids Res 46 2018 9253 9263 10.1093/nar/gky796 30219859 PMC6182178 · DOI
  59. [80]Chen Y.G. Hur S. Cellular origins of dsRNA, their recognition and consequences Nat Rev Mol Cell Biol 23 2022 286 301 10.1038/s41580-021-00430-1 34815573 PMC8969093 · DOI
  60. [81]Wu M.Z. Asahara H. Tzertzinis G. Roy B. Synthesis of low immunogenicity RNA with high-temperature in vitro transcription RNA 26 2020 345 360 10.1261/rna.073858.119 31900329 PMC7025508 · DOI
  61. [82]Dousis A. Ravichandran K. Hobert E.M. Moore M.J. Rabideau A.E. An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts Nat Biotechnol 41 4 2023 560 568 36357718 PMC10110463
  62. [83]Raskin C.A. Diaz G.A. McAllister W.T. T7 RNA polymerase mutants with altered promoter specificities Proc Natl Acad Sci U S A 90 1993 3147 3151 10.1073/pnas.90.8.3147 8475053 PMC46256 · DOI
  63. [84]Diaz G.A. Raskin C.A. McAllister W.T. Hierarchy of base-pair preference in the binding domain of the bacteriophage T7 promoter J Mol Biol 229 1993 805 811 10.1006/jmbi.1993.1086 8445647 · DOI
  64. [85]Beier H. Hausmann R. T3 times T7 phage crosses leading to recombinant RNA polymerases Nature 251 1974 538 540 10.1038/251538a0 4608344 · DOI
  65. [86]Klement J.F. Moorefiedl M.B. Jorgensen E. Brown J.E. Risman S. McAllister W.T. Discrimination between bacteriophage T3 and T7 promoters by the T3 and T7 RNA polymerases depends primarily upon a three base-pair region located 10 to 12 base-pairs upstream from the start site J Mol Biol 215 1 1990 21 29 2204706
  66. [87]Butler E.T. Chamberlin M.J. Bacteriophage SP6-specific RNA polymerase. I. Isolation and characterization of the enzyme J Biol Chem 257 10 1982 5772 5778 7040372
  67. [88]Krieg P.A. Melton D.A. In vitro RNA synthesis with SP6 RNA polymerase Methods Enzymol 155 1987 397 415 10.1016/0076-6879(87)55027-3 2828872 · DOI
  68. [89]Frye M. Jaffrey S.R. Pan T. Rechavi G. Suzuki T. RNA modifications: what have we learned and where are we headed? Nat Rev Genet 17 2016 365 372 10.1038/nrg.2016.47 27140282 · DOI
  69. [90]Roundtree I.A. Evans M.E. Pan T. He C. Dynamic RNA Modifications in Gene Expression Regulation Cell 169 2017 1187 1200 10.1016/j.cell.2017.05.045 28622506 PMC5657247 · DOI
  70. [91]Milisavljevic N. Perlikova P. Pohl R. Hocek M. Enzymatic synthesis of base-modified RNA by T7 RNA polymerase. A systematic study and comparison of 5-substituted pyrimidine and 7-substituted 7-deazapurine nucleoside triphosphates as substrates Org Biomol Chem 16 2018 5800 5807 10.1039/c8ob01498a 30063056 · DOI
  71. [92]Potapov V. Fu X. Dai N. Corrêa I.R. Tanner N.A. Ong J.L. Base modifications affecting RNA polymerase and reverse transcriptase fidelity Nucleic Acids Res 46 11 2018 5753 5763 29750267 PMC6009661
  72. [93]Chen T.H. Potapov V. Dai N. Ong J.L. Roy B. N(1)-methyl-pseudouridine is incorporated with higher fidelity than pseudouridine in synthetic RNAs Sci Rep 12 2022 13017 10.1038/s41598-022-17249-1 35906281 PMC9335462 · DOI
  73. [94]Fabrega C. Hausmann S. Shen V. Shuman S. Lima C.D. Structure and mechanism of mRNA cap (guanine-N7) methyltransferase Mol Cell 13 2004 77 89 10.1016/s1097-2765(03)00522-7 14731396 · DOI
  74. [96]Stepinski J. Waddell C. Stolarski R. Darzynkiewicz E. Rhoads R.E. Synthesis and properties of mRNAs containing the novel “anti-reverse” cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG RNA 7 2001 1486 1495 11680853 PMC1370192
  75. [98]Kis Z. Kontoravdi C. Shattock R. Shah N. Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand Vaccines (Basel) 9 1 2020 3 33374802 PMC7824664
  76. [99]Williams G.D. Gokhale N.S. Snider D.L. Horner S.M. Schoggins J. The mRNA Cap 2′- O -Methyltransferase CMTR1 Regulates the Expression of Certain Interferon-Stimulated Genes mSphere 5 3 2020 PMC7227766 32404510
  77. [100]Egloff M.P. Benarroch D. Selisko B. Romette J.L. Canard B. An RNA cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization EMBO J 21 2002 2757 2768 10.1093/emboj/21.11.2757 12032088 PMC125380 · DOI
  78. [101]Fuchs A.L. Neu A. Sprangers R. A general method for rapid and cost-efficient large-scale production of 5' capped RNA RNA 22 2016 1454 1466 10.1261/rna.056614.116 27368341 PMC4986899 · DOI
  79. [103]Plotkin S. Robinson J.M. Cunningham G. Iqbal R. Larsen S. The complexity and cost of vaccine manufacturing - An overview Vaccine 35 2017 4064 4071 10.1016/j.vaccine.2017.06.003 28647170 PMC5518734 · DOI
  80. [104]Whitley J. Zwolinski C. Denis C. Maughan M. Hayles L. Clarke D. Snare M. Liao H. Chiou S. Marmura T. Zoeller H. Hudson B. Peart J. Johnson M. Karlsson A. Wang Y. Nagle C. Harris C. Tonkin D. Fraser S. Capiz L. Zeno C.L. Meli Y. Martik D. Ozaki D.A. Caparoni A. Dickens J.E. Weissman D. Saunders K.O. Haynes B.F. Sempowski G.D. Denny T.N. Johnson M.R. Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials Transl Res 242 2022 38 55 34871810 PMC8641981
  81. [105]Rosa S.S. Prazeres D.M.F. Azevedo A.M. Marques M.P.C. mRNA vaccines manufacturing: Challenges and bottlenecks Vaccine 39 2021 2190 2200 10.1016/j.vaccine.2021.03.038 33771389 PMC7987532 · DOI · Paper page
  82. [106]Karikó K. Muramatsu H. Ludwig J. Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA Nucleic Acids Res 39 21 2011 e142 21890902 PMC3241667
  83. [107]Meyer, R. A., Trabulo, S., Douthwaite, J. A. & Santos, J. L. in Messenger RNA Therapeutics (eds Stefan Jurga & Jan Barciszewski) 1-16 (Springer International Publishing, 2022).
  84. [108]Chien K.R. Zangi L. Lui K.O. Synthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine Cold Spring Harb Perspect Med 5 1 2015 PMC4292072 25301935
  85. [109]Lorentzen C.L. Haanen J.B. Met O. Svane I.M. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment Lancet Oncol 23 2022 e450 e458 10.1016/S1470-2045(22)00372-2 36174631 PMC9512276 · DOI
  86. [111]Zhang M. Hussain A. Yang H. Zhang J. Liang X.-J. Huang Y. mRNA-based modalities for infectious disease management Nano Res 16 1 2023 672 691 35818566 PMC9258466
  87. [114]Zhang X. Zhao W. Nguyen G.N. Zhang C. Zeng C. Yan J. Du S. Hou X. Li W. Jiang J. Deng B. McComb D.W. Dorkin R. Shah A. Barrera L. Gregoire F. Singh M. Chen D. Sabatino D.E. Dong Y. Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing Sci Adv 6 34 2020 10.1126/sciadv.abc2315 PMC7442477 32937374 · DOI
  88. [115]Ramaswamy S. Tonnu N. Tachikawa K. Limphong P. Vega J.B. Karmali P.P. Chivukula P. Verma I.M. Systemic delivery of factor IX messenger RNA for protein replacement therapy Proc Natl Acad Sci U S A 114 10 2017 10.1073/pnas.1619653114 PMC5347596 28202722 · DOI · Paper page
  89. [117]Li Y. Teague B. Zhang Y. Su Z. Porter E. Dobosh B. Wagner T. Irvine D.J. Weiss R. In vitro evolution of enhanced RNA replicons for immunotherapy Sci Rep 9 1 2019 10.1038/s41598-019-43422-0 PMC6502795 31061426 · DOI · Paper page
  90. [118]Beissert T. Perkovic M. Vogel A. Erbar S. Walzer K.C. Hempel T. Brill S. Haefner E. Becker R. Türeci Ö. Sahin U. A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity Mol Ther 28 1 2020 119 128 31624015 PMC6953774
  91. [119]Maruggi G. Ulmer J.B. Rappuoli R. Yu D. Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action Curr Top Microbiol Immunol 2021 10.1007/82_2021_233 33861374 · DOI
  92. [121]Mandl C.W. Aberle J.H. Aberle S.W. Holzmann H. Allison S.L. Heinz F.X. In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model Nat Med 4 12 1998 1438 1440 9846585
  93. [122]Ulmer J.B. Mason P.W. Geall A. Mandl C.W. RNA-based vaccines Vaccine 30 2012 4414 4418 10.1016/j.vaccine.2012.04.060 22546329 · DOI
  94. [124]Liu Y. Chin J.M. Choo E.L. Phua K.K.L. Messenger RNA translation enhancement by immune evasion proteins: a comparative study between EKB (vaccinia virus) and NS1 (influenza A virus) Sci Rep 9 2019 11972 10.1038/s41598-019-48559-6 31427778 PMC6700162 · DOI
  95. [125]Beissert T. Koste L. Perkovic M. Walzer K.C. Erbar S. Selmi A. Diken M. Kreiter S. Türeci Ö. Sahin U. Improvement of In Vivo Expression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins Hum Gene Ther 28 12 2017 1138 1146 28877647 PMC5737720
  96. [128]Du S. Li W. Zhang Y. Xue Y. Hou X. Yan J. Cheng J. Deng B. McComb D.W. Lin J. Zeng H. Cheng X. Irvine D.J. Weiss R. Dong Y. Cholesterol‐Amino‐Phosphate (CAP) Derived Lipid Nanoparticles for Delivery of Self‐Amplifying RNA and Restoration of Spermatogenesis in Infertile Mice Advanced Science 10 11 2023 PMC10104632 36748274
  97. [129]Wagner T.E. Becraft J.R. Bodner K. Teague B. Zhang X. Woo A. Porter E. Alburquerque B. Dobosh B. Andries O. Sanders N.N. Beal J. Densmore D. Kitada T. Weiss R. Small-molecule-based regulation of RNA-delivered circuits in mammalian cells Nat Chem Biol 14 11 2018 1043 1050 30327560
  98. [131]Chen L.L. The expanding regulatory mechanisms and cellular functions of circular RNAs Nat Rev Mol Cell Biol 21 2020 475 490 10.1038/s41580-020-0243-y 32366901 · DOI
  99. [132]Qian L. Vu M.N. Carter M. Wilkinson M.F. A spliced intron accumulates as a lariat in the nucleus of T cells Nucleic Acids Res 20 1992 5345 5350 10.1093/nar/20.20.5345 1437551 PMC334340 · DOI
  100. [133]Barrett S.P. Wang P.L. Salzman J. Circular RNA biogenesis can proceed through an exon-containing lariat precursor Elife 4 2015 e07540 26057830 PMC4479058
  101. [134]Obi P. Chen Y.G. The design and synthesis of circular RNAs Methods 196 2021 85 103 10.1016/j.ymeth.2021.02.020 33662562 PMC8670866 · DOI
  102. [135]Liu X. Zhang Y.u. Zhou S. Dain L. Mei L. Zhu G. Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines J Control Release 348 2022 84 94 35649485 PMC9644292
  103. [136]Nandakumar J. Ho C.K. Lima C.D. Shuman S. RNA substrate specificity and structure-guided mutational analysis of bacteriophage T4 RNA ligase 2 J Biol Chem 279 2004 31337 31347 10.1074/jbc.M402394200 15084599 · DOI
  104. [137]Lang K. Micura R. The preparation of site-specifically modified riboswitch domains as an example for enzymatic ligation of chemically synthesized RNA fragments Nat. Protoc. 3 2008 1457 1466 10.1038/nprot.2008.135 18772873 · DOI
  105. [138]Puttaraju M. Been M.D. Group I permuted intron-exon (PIE) sequences self-splice to produce circular exons Nucleic Acids Res 20 1992 5357 5364 10.1093/nar/20.20.5357 1279519 PMC334342 · DOI
  106. [140]Loan Young T. Chang Wang K. James Varley A. Li B. Clinical delivery of circular RNA: Lessons learned from RNA drug development Advanced Drug Delivery Reviews 197 2023 114826 10.1016/j.addr.2023.114826 37088404 · DOI
  107. [141]Lee K.H. Kim S. Lee S.-W. Pros and cons of in vitro methods for circular RNA Preparation Int. J. Mol. Sci. 23 21 2022 13247 36362032 PMC9654983
  108. [142]Garber K. Orna Therapeutics: circular logic Nat. Biotechnol. 2022 10.1038/d41587-022-00005-1 35931823 · DOI
  109. [143]Abe N. Matsumoto K. Nishihara M. Nakano Y. Shibata A. Maruyama H. Shuto S. Matsuda A. Yoshida M. Ito Y. Abe H. Rolling circle translation of circular RNA in Living Human Cells Sci. Rep. 5 1 2015 10.1038/srep16435 PMC4639774 26553571 · DOI
  110. [144]Chen R. Wang S.K. Belk J.A. Amaya L. Li Z. Cardenas A. Abe B.T. Chen C.-K. Wender P.A. Chang H.Y. Engineering circular RNA for enhanced protein production Nat. Biotechnol. 41 2 2023 262 272 35851375 PMC9931579
  111. [145]Li S. Wu H. Chen L.L. Screening circular RNAs with functional potential using the RfxCas13d/BSJ-gRNA system Nat. Protoc. 17 2022 2085 2107 10.1038/s41596-022-00715-5 35831613 · DOI
  112. [146]Nielsen A.F. Bindereif A. Bozzoni I. Hanan M. Hansen T.B. Irimia M. Kadener S. Kristensen L.S. Legnini I. Morlando M. Jarlstad Olesen M.T. Pasterkamp R.J. Preibisch S. Rajewsky N. Suenkel C. Kjems J. Best practice standards for circular RNA research Nat. Methods 19 10 2022 1208 1220 35618955 PMC9759028

Cited by

Sorted by citations

Authors
Kang, D. D., Li, H., & Dong, Y.
Affiliations
Tisch Cancer Institute (US)
Corresponding author
Dong, Yizhou
ORCID
Venue
Advanced Drug Delivery Reviews
Publisher
Elsevier BV
Published
2023-08
Volume
199
Pages
114961
ISSN
0169-409X (ISSN-L)
DOI
10.1016/j.addr.2023.114961
PMC
PMC10264168
OpenAlex
W4380793095
Cited by
100
References
35
Citations by year
2026: 21 · 2025: 47 · 2024: 28 · 2023: 4
FWCI
2.58
Type
journal article
Language
en
Open access
Licence
Locations
  • Advanced Drug Delivery Reviews (acceptedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of General Medical Sciences (R35GM144117)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Keywords
in vitro transcribed mRNA, mRNA vaccines, mRNA therapeutics, SARS-CoV-2, mRNA synthesis, genome editing, clinical translation
MeSH terms
COVID-19, SARS-CoV-2, Humans, Neoplasms, RNA, Messenger, Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review